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IntedanibTyrosine kinases regulate a broad variety of physiological cell processes, including metabolism, growth, dif-
ferentiation and apoptosis. Abnormal tyrosine kinase activity disturbs the physiological cell homeostasis
and can lead to cancer, vascular disease, and ﬁbrosis. In regard to ﬁbrosis, different tyrosine kinases have
been identiﬁed as determinants of disease progression and potential targets for anti-ﬁbrotic therapies. This
includes both receptor tyrosine kinases (e.g., PDGF receptor, VEGF receptor, EGF receptor, and JAK kinases)
as well as non-receptor tyrosine kinases (e.g., c-Abl, c-Kit, and Src kinases). Given their central role in the
pathogenesis of ﬁbrosis, researchers of our ﬁeld study the anti-ﬁbrotic effects of monoclonal antibodies or
small-molecule inhibitors to block the aberrant tyrosine kinase activity and treat ﬁbrosis in preclinical
models of various ﬁbrotic diseases (e.g., idiopathic pulmonary ﬁbrosis, renal ﬁbrosis, liver ﬁbrosis, and der-
mal ﬁbrosis). The results of these studies were promising and prompted clinical trials with different com-
pounds in ﬁbrotic diseases. So far, results from studies with intedanib in idiopathic pulmonary ﬁbrosis and
imatinib in idiopathic pulmonary ﬁbrosis and systemic sclerosis have been reported. Although none of
these studies reported a positive primary outcome, promising trends in anti-ﬁbrotic efﬁcacy awaken our
hopes for a new class of effective anti-ﬁbrotic targeted therapies. This article is part of a Special Issue entitled:
Fibrosis: Translation of basic research to human disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Tyrosine kinases regulate awide variety of physiological cell process-
es, including metabolism, growth, differentiation, and apoptosis. The
commonmode of action of tyrosine kinases is phosphorylation of target
proteins at tyrosine residues, which allows formation of multiprotein
complexes critical in signal transduction. Depending on their localiza-
tion in the cell, tyrosine kinases can be classiﬁed in two major groups:
the receptor tyrosine kinases are membrane receptors that activate in-
tracellular signaling pathways upon ligand binding to their extracellular
domains. For most of the receptor tyrosine kinases, this process includes
the di- or oligomerization of tyrosine kinase monomers, followed by
autophosphorylation of the intracellular kinase domain to increase the
catalytic activity. After autophosphorylation, the receptor tyrosine ki-
nases recruit and phosphorylate cytoplasmic signaling molecules either
directly or indirectly via docking proteins that are also phosphorylated
by receptor tyrosine kinases [1]. In contrast to receptor tyrosine kinases,
non-receptor tyrosine kinases lack extracellular and transmembranes: Translation of basic research
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rights reserved.domains butmodulate signalingpathwayswithin the cytoplasm. Similar
to receptor tyrosine kinases, phosphorylation and autophosphorylation
lead to activation of non-receptor tyrosine kinases [2].
Given the central role of receptor and non-receptor tyrosine kinases
in cell signaling, deregulated tyrosine kinase activity can promote the de-
velopment and progression of neoplastic, cardiovascular, andﬁbrotic dis-
eases. In this context, pathologic activation of tyrosine kinases can drive
cancerogenesis, vascular remodeling, and ﬁbrogenesis [3–5], suggesting
that restoral of normal tyrosine kinase activity may be an effective treat-
ment approach in each of these conditions. So far, two different pharma-
cological strategies can target the pathologic tyrosine kinase activity:
monoclonal antibodies block the extracellular domains of receptor tyro-
sine kinases, while small molecule inhibitors enter the cell and block ki-
nase domains of both receptor and non-receptor tyrosine kinases. Of
note, several compounds of both classes are already considered ﬁrst-
line therapies in various malignancies. This includes antibodies against
epithelial growth factor (EGF) receptor (e.g., trastuzumab) in HER2-
positive breast cancer patients or the small molecule inhibitor imatinib,
which blocks the aberrant activity of the Abelson kinase in chronic mye-
logenous leukemia (CML). Interestingly, treatment of CML with imatinib
provided the ﬁrst clinical evidence for potential anti-ﬁbrotic effects of ty-
rosine kinase inhibition: imatinib led to regression of bonemarrowﬁbro-
sis in CML patients, an effect independent of the anti-tumor activity [6,7].
Stimulated by these ﬁndings, research in our ﬁeld intensiﬁed basic and
translational studies on the role of tyrosine kinases in the development
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ment of ﬁbrotic diseases.
Pathologic activation of ﬁbroblasts and related cells is a hallmark of
ﬁbrotic diseases, including idiopathic pulmonary ﬁbrosis (IPF), renal ﬁ-
brosis, liver ﬁbrosis or systemic sclerosis (SSc). During early stages of ﬁ-
brotic disease, tissue damage and inﬂammation are thought to activate
ﬁbroblasts, while para- and autostimulatory loops may dominate later
disease stages. Once activated, ﬁbroblasts can express contractile pro-
teins (e.g., α-smooth muscle actin) and release excessive amounts of
extracellular matrix components. The ﬁbrotic process culminates in
pathologic tissue scarring and failure of the affected organs.
As we will discuss in this review, various tyrosine kinases play key
roles in the pathologic activation of ﬁbroblasts during ﬁbrogenesis
(Fig. 1), rendering them attractive molecular targets in the treatment
of ﬁbrosis. Paying tribute to the large body of evidence, we will partic-
ularly focus on the role of tyrosine kinases in SSc but also highlight
important ﬁndings in other ﬁbrotic diseases. The ﬁrst part of our re-
view will describe the molecular pathways of pro-ﬁbrotic tyrosine ki-
nase activity as well as translational ﬁndings obtained with tyrosine
kinase inhibitors in experimental models of ﬁbrosis. In the second
part, we will discuss recent ﬁndings of published clinical trials with
tyrosine kinase inhibitors in SSc and other ﬁbrotic diseases.
2. Tyrosine kinases as modulators of ﬁbroblast activation
2.1. PDGF receptors
The platelet derived growth factor receptors (PDGFRs)α andβ are re-
ceptor tyrosine kinases that bind members of the PDGF family of growth
factors. Upon activation, PDGFR monomers hetero- or homodimerize to
PDGFRαα, PDGFRαβ and PDGFRββ to induce autophosphorylation and
activate downstream signaling cascades. PDGFRα and β show similar
structures and activate overlapping signal transduction pathways, includ-
ing phosphatidylinositol 3 kinase (PI3K), Ras-MAP kinases, Src family ki-
nases and phospholipase Cγ (PLCγ), which results in partly overlapping
biological activities. In addition todimerization of distinct receptormono-
mers, PDGF ligands (i.e., PDGF-A, B, C and D) form different homo- or
heterodimers that vary in their afﬁnity for the different receptor com-
plexes [8].
PDGF-A/PDGFRα and PDGF-B/PDGFRβ interactions have different
biological roles. In general, PDGF-B/PDGFRβ-signaling appears to beFig. 1. Tyrosine kinaseswith central roles in ﬁbrosis. Receptor tyrosine kinases, including PDGF
Src kinases, stimulate the pathological synthesis and release of extracellular matrix (ECM) proprominent in vascular remodeling, both for normal homeostasis and
pathologic conditions. For example, pericyte coverage of blood vessels
is particularly dependent on PDGF-B/PDGFRβ-signaling [9]. PDGF-B is
primarily released by macrophages and hepatic stellate cells, with the
latter ones also pointing to a major role of PDGF-B/PDGFRβ-signaling
in liver ﬁbrosis [10,11]. By contrast, PDGF-A/PDGFRα signaling appears
to have a broader role in tissue homeostasis and repair, in particular in
the skin, lungs, gut and kidneys. Fibroblasts and ﬁbroblast-like cells are
both major sources and targets for PDGF-A since they express PDGFRα
on their cell surface [12–14]. Thus, paracrine and autocrine PDGF-A/
PDGFRα signaling loops can stimulate ﬁbroblasts to synthesize extra-
cellular matrix and release pro-ﬁbrotic mediators. Discovered more re-
cently, the roles of PDGF-C and D in tissue homoeostasis and ﬁbrotic
disease of various organs are less well-deﬁned. While PDGF-C may pri-
marily activate PDGFRα, PDGFRβ appears to be the main receptor for
PDGF-D [15].
PDGF signaling remains silent in most normal tissues but becomes
activated upon tissue injury to promote wound closure and scar forma-
tion. During wound healing, PDGF signaling is tightly regulated and
turned off as soon as the repair processes are completed [16]. Uncon-
trolled activation or failure to terminate activated PDGF signaling may
lead to excessive scar formation and tissue ﬁbrosis. In this context, en-
hanced PDGF signaling has been described in pulmonary ﬁbrosis and
SSc (mainly PDGF-A via PDGFRα) as well as in liver ﬁbrosis (PDGF-B
via PDGFRβ). In addition, there is increasing evidence for pro-ﬁbrotic ef-
fects of PDGF-C andD (via PDGFRα and PDGFRβ) in the liver and the kid-
neys [15,17–21]. Of note, an additional, PDGF-independent mechanism
may activate PDGF signaling in SSc: stimulatory autoantibodies directed
against the PDGF receptorswere found to be capable of stimulating reac-
tive oxygen species to activate pro-ﬁbrotic ERK signaling [22].
The role of PDGF signaling in the development of tissue ﬁbrosis is
further corroborated by murine models harboring mutations for the
PDGF receptor α or β. Animals with activating mutations for the PDGF
receptor α develop progressive ﬁbrosis of the skin, gastrointestinal
tract, kidneys, heart, and skeletal muscles, but do not show perturbed
vascular integrity and smooth muscle activity, which is consistent to
the minor role of PDGF-A/PDGFRα signaling in blood vessels [14]. In
contrast, experimental activation of PDGFRβ has a major impact on
cell proliferation in aortic smooth muscle cells in vivo [9].
Given the central role of PDGF in tissue ﬁbrosis, blockade of the
PDGFR appears to be a promising anti-ﬁbrotic treatment approach.R, VEGFR, EGFR and JAK kinases as well as non-receptor tyrosine kinases, such as c-Abl and
teins.
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nase domain of the PDGFR. Apart from its effects on PDGF signaling,
imatinib also interferes with the tyrosine kinases c-Abl and c-Kit,
which are discussed later in this review [23]. In vitro and in vivo,
blockade of the PDGFR by imatinib inhibited the activation of ﬁbro-
blasts, the release of extracellularmatrix and the development of exper-
imentalﬁbrosis inmodel systems for dermal, pulmonary, renal and liver
ﬁbrosis [24–29]. In some models, imatinib was effective in preventing
the development of ﬁbrosis aswell as reducing established ﬁbrosis [30].
Since most studies evaluating pharmacological PDGF blockade in ﬁ-
brosis have used imatinib, which inhibits the PDGF receptorsα and β, it
remains unclear if combined or selective targeting of the PDGF receptor
isoforms is favorable. This issue is even further complicated with
imatinib blocking c-Abl and c-Kit. Because of the partially overlapping
effects of both receptor isoforms, combined blockade might have supe-
rior efﬁcacy. Blocking both isoforms, however, harbors greater risks for
side effects. In particular in patients with SSc, inhibition of PDGF-B/
PDGFRβ may exacerbate vascular disease complications by interfering
with pericyte function.
2.2. VEGF receptors
VEGF signaling shows a similar complexity as the PDGF network.
Five different VEGF ligands (VEGF-A, B, C, D and placental growth factor
[PLGF]) as well as three different receptors (VEGFR1, 2 and 3) transmit
speciﬁc signals to modulate downstream information. Of note, splicing
variants of VEGF-A can further ﬁne tune VEGF signaling [31]. VEGF-A,
-B andPLGF bind to VEGFR1, and VEGF-A is a ligand of VEGFR2. In regard
to their biological functions, VEGF-A is a key mediator of angiogenesis
and other cellular processes in adults, while VEGF-B is primarily active
during embryogenesis. VEGF-C andVEGF-D, but not VEGF-A, are ligands
for a third receptor (VEGFR3), stimulating lymphangiogenesis [31]. The
VEGFRs are receptor tyrosine kinases with VEGFR2 mediating most
of the cellular responses to VEGF to promote vessel formation and
vascular integrity [32]. The role of VEGFR1 is more complex: During
vasculo- and angiogenesis, VEGFR1 can dampen VEGFR2 responses
by trapping VEGF-A or by direct receptor-crosstalk with VEGFR2
[33–35]. In pathological conditions such as ischemia, inﬂammation,
wound healing and cancer, however, VEGFR1 may also synergize
with VEGFR2 activity in a PLGF-dependent manner [36].
The link between VEGF signaling and ﬁbrosis may involve direct and
indirect mechanisms. Since vascular damage and loss of capillaries are
major features in SSc, VEGF signaling is likely to be disturbed. Instead
of decreased VEGF signaling as initially suspected, however, VEGF-A
levels and VEGFR1 and 2 are strongly up-regulated in SSc skin [37].
This paradox has long been subject of intensive investigations: the ﬁrst
hypotheses assumed that VEGF-driven, angiogenic processes might be
futile and even deleterious in SSc, since sufﬁcient tissue angiogenesis de-
pends on strict regulation of VEGF expression [38–40]. In addition, re-
cent experimental evidence demonstrates that anti-angiogenic splicing
variants of VEGF-A are selectively overexpressed in SSc, which can im-
pair the formation of functional blood vessels [41]. In particular these re-
cent ﬁndingsmaymark a breakthrough in solving the paradox of severe
small-vessel vasculopathy and the—at least seemingly—enhanced vas-
cular response in SSc.
Apart from its central role in SSc vascular disease, there is growing
evidence that VEGF/VEGFR signaling has mitogenic and pro-ﬁbrotic
effects on ﬁbroblasts. Recent evidence from transgenic mouse models
demonstrates that VEGF-A signaling itself can stimulate the produc-
tion of extracellular matrix proteins [42], providing a potential link
between vascular changes and ﬁbrosis in SSc. VEGF-A may also have
pro-ﬁbrotic effects in retinal and renal diseases [43–46] in which
pathological vascular changes and scar formation are also dominant
disease features.
The evidence for a pro-ﬁbrotic role of VEGF signaling, however, is still
limited. Future research will need to diligently address the complexVEGF network with its various ligand and receptor subtypes in model
systems for different ﬁbrotic diseases. Nevertheless, some of the multi-
tyrosine kinase inhibitors already used in clinical trials for ﬁbrotic dis-
eases (as discussed later) also show anti-VEGF activity, which might
contribute to their anti-ﬁbrotic activity. Apart from beneﬁcial effects,
however, VEGF receptor blockade harbors potential risks, in particular
in patients with SSc vasculopathy. Although controlled inhibition of
VEGF signaling might counterbalance the overexpression of the VEGF
axis to improve SSc vascular disease, complete blockade of VEGF signal-
ing by tyrosine kinase inhibitors could abrogate angiogenesis and wors-
en vascular diseasemanifestations. Apart fromnegative effects on small-
vessel vasculopathy, anti-VEGF therapies may increase the risk for renal
protein excretion and hypertension [47]. In this regard, interference
with VEGF-signaling could hypothetically increase the risk for renal
complications in patients with SSc (i.e., renal crisis).
2.3. EGF receptors
EGF ligands bind to a complex system of receptor tyrosine ki-
nases, called the ErbB system. The ErbB system is composed of four
membrane-associated proteins, ErbB1 (also known as EGFR), ErbB2
(an orphan receptor), ErbB3 and ErbB4. Apart from EGF, transforming
growth factor-α (TGF-α), heparin-binding EGF-like growth factor,
amphiregulin, neuregulin, betacellulin, epiregulin and epigen bind to
ErbB receptors. Similar to PDGF and VEGF signaling, differential binding
of EGF ligands to the ErbBs initiates homodimeric or heterodimeric recep-
tor dimerization to induce autophosphorylation of intracellular kinase
domains and downstream cell signaling through mitogen-activated pro-
tein (MAP) kinases, phosphatidylinositol 3-kinase (PI3K), and transcrip-
tion factors including STAT3 [48,49]. Interestingly, EGF receptor may
stimulate angiogenesis in tumors by up-regulation of VEGF linking
tumor growthwith angiogenesis [50]; similarmechanismsmay be active
in ﬁbrosis, which, however, needs experimental conﬁrmation.
EGF signaling has been implicated into the pathogenesis of pulmo-
nary and renal ﬁbrosis, but only little evidence exists for other ﬁbrotic
diseases such as liver ﬁbrosis or skin ﬁbrosis so far [51]. In the lungs,
EGF signaling is critical for epithelial–mesenchymal interactions dur-
ing both healthy states and disease. In this context, EGF signaling acts
as an important survival factor for the lung epithelium, but also pro-
motes ﬁbroblast proliferation and extracellular matrix production.
In general, the pro-ﬁbrotic effects of EGF signaling appear to be dele-
terious and promote disease progression in pulmonary ﬁbrosis. Most
of the genetic and pharmacological studies indicate that stimulation
of EGF signaling exacerbates experimental pulmonary ﬁbrosis, while
its inhibition is protective [52–58]. The molecular effects of EGF sig-
naling in pulmonary ﬁbrosis, however, seem to be more complex.
Certain EGF ligands, such as amphiregulin, have shown anti-ﬁbrotic
effects in models of pulmonary ﬁbrosis [59]. Moreover, EGF ligand—
receptor interactions that are otherwise associated with disease pro-
gression may show protective effects in certain disease models and
states of lung ﬁbrosis. Experimental overexpression of TGF-α, for
example, protected mice from nickel-induced lung injury [60,61].
In another study, the selective EGFR inhibitor ZD1839 exacerbated
bleomycin-induced pulmonary ﬁbrosis [62]. Of note, approximate-
ly 1% of patients with lung cancer receiving the EGFR inhibitors
(e.g., geﬁtinib and erlotinib) develop interstitial lung disease. Risk
factors include Asian ethnicity, older age, smoking, preexisting ILD,
and concurrent cardiac disease among others [63–65]. Thus, under cer-
tain circumstances, targeting of EGF signaling may also worsen ﬁbrosis,
which warrants great attention when evaluating EGFR blocking agents
in patients suffering from ﬁbrotic diseases.
In renal physiology and pathology, EGF signaling appears to have sim-
ilar effects as in the lungs, including regulationof epithelial–mesenchymal
interactions. Several EGF ligands, such as heparin-binding EGF and TGF-α,
are expressed by renal epithelial cells and released after injury. These li-
gands can bind to EGFR expressed on both renal interstitial ﬁbroblasts
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be involved in renalﬁbrogenesis, because experimental overexpression of
the dominant negative isoform of EGFR in renal tubular cells attenuated
the renalﬁbrotic lesions inducedbyprolonged renal ischemia and chronic
infusion of angiotensin II [67,68]. In renal ﬁbrosis, the pro-ﬁbrotic effects
of EGFR signalingmay be, at least in part,mediated by TGFβ [69,70]. Final-
ly, genetic or pharmacologic blockade of EGFR can inhibit experimental
renal ﬁbrosis [71], suggesting that inhibition of EGFR signaling might be
an interesting therapeutic target in the treatment of ﬁbrotic renal disease.
Potential protective effects of EGF signaling, as observed in pulmonary ﬁ-
brosis, have not yet been described for renal ﬁbrosis.
2.4. JAK2 kinases
Janus kinases (JAKs) are receptor-associated tyrosine kinases with
central roles in cytokine- and growth factor signaling. The JAK proteins
have seven JAK homology (JH) domains [72]. Whereas the JH1 kinase
domain phosphorylates target molecules to activate downstream sig-
naling, the JH2 domain is a dual-speciﬁcity protein kinase that phos-
phorylates two negative regulatory sites in JAK2 [73]. The remaining
domains (JH3 to JH7) are necessary for protein–protein interactions
with cytokine receptors and signal transducers and activators of tran-
scription (STAT) proteins [72]. In analogy to other receptor tyrosine ki-
nases, cytokine binding induces autophosphorylation and activation of
JAK kinases [74]. In turn, JAK kinases recruit and phosphorylate STAT
proteins. Upon activation, STATs dimerize and translocate into the nu-
cleus where they activate the transcription of several target genes
[74]. Apart from the canonical JAK–STAT signaling, a portion of nuclear,
unphosphorylated STAT regulates heterochromatin stability, which
does not require induction of STAT transcriptional target genes [75].
JAK2 is a key-regulator of cytokine signaling, and alterations of
JAK2 signaling cause profound changes in response to cytokine stim-
ulation. Point mutations in the JAK2 gene, which result in constitutive
activation of JAK2, are key-events in the pathogenesis of myeloprolif-
erative diseases [74,76,77]. We studied JAK2 in SSc and experimental
skin ﬁbrosis. We observed that TGFβ signaling can induce phosphor-
ylation and activation of JAK2, which then interacts with phosphory-
lated STAT3 to induce ﬁbrotic responses. Interestingly, JAK2 may not
only be a downstream target of TGFβ in ﬁbroblasts but also amplify
TGFβ signaling by stimulating the expression of TGFβ. In this context,
both inhibition of STAT3 and overexpression of SOCS1, an endoge-
nous suppressor of STAT signaling, reduced the expression of TGFβ
[78,79]. Finally, inhibition of JAK2 was effective in inhibiting the de-
velopment of ﬁbrosis in several experimental models, suggesting
that JAK2 inhibitors might be promising therapies for patients with ﬁ-
brotic diseases. As several JAK2 inhibitors are currently evaluated in
clinical trials for malignancies and rheumatoid arthritis, the anti-
ﬁbrotic effects in experimental models of ﬁbrosis may have direct
translational implications.
2.5. c-Abl and c-Kit
c-Abl and c-Kit are non-receptor tyrosine kinases with crucial roles
in the development of malignancies. While pathological c-Abl activity
is the driving force in CML, activating c-Kit mutations induces and pro-
motes the development of gastro-intestinal stromal tumors (GIST). In
CML, a genetic translocation fusing c-Abl to the breakpoint cluster re-
gion (bcr) results in permanent activation of c-Abl, which has strong
mitogenic effects. Treatment with imatinib can inhibit the pathologic
c-Abl activity in CML and induce tumor regression. In the vast majority
of gastrointestinal stromal tumors, signaling via c-Kit or PDGF receptors
is constitutively activated [80,81], rendering imatinib, which blocks
both tyrosine kinases, an effective treatment [82].
Several studies suggest that the anti-ﬁbrotic effects of imatinib
and similar small molecule inhibitors, such as nilotinib and dasatinib,
are not only mediated by blocking PDGF signaling but also by inhibitingc-Abl and c-Kit. In their landmark work on the anti-ﬁbrotic effects
of imatinib in experimental lung ﬁbrosis, Daniels and colleagues
suggested that inhibition of c-Abl may be a main mode of action
for the anti-ﬁbrotic effects of imatinib. The authors identiﬁed c-Abl
as a smad-independent downstream target of the pro-ﬁbrotic
TGFβ-signaling [27]. We observed that imatinib (as well as nilotinib
and dasatinib) inhibited both TGFβ- and PDGF-induced collagen re-
lease from ﬁbroblasts [23,25]. Our results are in line with studies in
other pro-ﬁbrotic diseases that also suggest a more nuanced situa-
tion with anti-ﬁbrotic effects of imatinib and related TKIs mediated
by both TGFβ- and PDGF-dependent pathways [26,28,29,83].
The role of c-Kit in ﬁbrosis appears to be even more complex since
it is usually expressed in only a few cell types including stem cells,
mast cells, melanocytes in the skin and Cajal cells in the intestine
[84]. c-Kit activity in mast cells has been linked to different ﬁbrotic
conditions [85,86], and some authors suggest that c-Kit might be
expressed in ﬁbroblasts during wound healing and tissue ﬁbrosis
[87]. Nevertheless, future studies need to conﬁrm these ﬁndings and
more clearly deﬁne the role of c-Kit in ﬁbrosis. This may also help to
better dissect the different targets and pathways by which imatinib
and similar small molecule inhibitors reduce ﬁbrosis.
2.6. Src kinases
Src kinases, a family of non-receptor tyrosine kinases, are important
mediators of pro-ﬁbrotic signaling pathways. For example, Src kinases
modulate the activity of TGFβ signaling by phosphorylating and activat-
ing TGFβ type II receptor and the downstream target c-Abl [88,89]. Src
kinases are activated by increased levels of reactive oxygen species or
pro-ﬁbrotic cytokines, including TGFβ, PDGF and angiotensin-2, all of
which are present in pro-ﬁbrotic diseases [69,90–92]. The central pro-
ﬁbrotic role of Src kinases is conﬁrmed by potent anti-ﬁbrotic effects
of the speciﬁc Src kinase inhibitor SU6656 in experimental ﬁbrosis
[90,93]. Thus, targeting Src kinases may be another promising approach
in the treatment of SSc and other ﬁbrotic diseases. Although selective
inhibitors of Src kinases are not yet in clinical use, the tyrosine kinase in-
hibitor dasatinib inhibits Src kinases in pharmacologically relevant con-
centrations in addition to inhibition of PDGF and c-Abl. A clinical proof-
of-concept study with dasatinib in patients with SSc is ongoing.
3. Clinical trials with tyrosine kinase inhibitors in ﬁbrotic diseases—
lessons to be learned
3.1. Systemic sclerosis
Effective and tolerable anti-ﬁbrotic therapies are not available in
clinical routine but are urgently needed because of the high morbidity
andmortality of SSc and other ﬁbrotic diseases. As discussed in the pre-
vious sections, results from pre-clinical models suggest that imatinib
and similar tyrosine kinase inhibitors (e.g., dasatinib and nilotinib)
may have anti-ﬁbrotic effects in SSc [23,25]. Given these preclinical
ﬁndings and the good tolerability in patients with CML, several clinical
trials with imatinib in patients with progressive, diffuse-cutaneous SSc
have been performed [94–97]. In these trials, patients received doses
of 400 mg up to 600 mg imatinib daily.
At ﬁrst consideration, the results of these trials are disappointing.
Although most of the studies showed a trend towards improvement
of skin [94,95,97] and lung ﬁbrosis [95,97], unexpectedly high rates
of adverse events led to the withdrawal of imatinib in many patients.
The spectrum of adverse effects included edema, fatigue, nausea and
vomiting, diarrhea, generalized rash, new onset proteinuria, and mus-
cle weakness, among others. In particular the rate and severity of pe-
ripheral edema were unexpected, when compared to the data from
the CML trials [98–101], and led to the withdrawal of imatinib in
many patients with SSc. Thus, on this ﬁrst glance, these results
might not support the use of imatinib in SSc.
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ever, a close look at the results of these trials reveals several short-
comings [102]. (i) Effectively all of these trials had a non-controlled
design, which does not allow making ﬁnal conclusions. One study
had been designed as a randomized-controlled trial but just included
one patient in its placebo group. (ii) Most patients suffered from se-
vere disease including patients with lung involvement and active
alveolitis [94,95]. Given the diversity of SSc disease manifestations,
most of the spectrum of complications could, at least in part, repre-
sent features of SSc rather than adverse events. (iii) Concomitant
therapy with methotrexate might have also contributed to the high
rates of complications [96].
Because of these limitations, ﬁnal conclusions of the anti-ﬁbrotic
effects of imatinib in patients with SSc are currently impossible. In
particular with the high rate of vascular complications, there are con-
cerns that interference of imatinib with PDGF-B/PDGFRβ signaling
might further impair pericyte function and vascular repair processes,
resulting in exacerbations of SSc vasculopathy with the development
of peripheral edema. Of note, the increased rate of peripheral edema
might have also confounded the results of the modiﬁed Rodnan skin
score [103–106], which is the standard primary outcome measure in
SSc trials. Peripheral edema can be hard to discriminate from severe
skin involvement by SSc, which could lead to increased scoring by
skin score.
Thus, many open questions in regard to both efﬁcacy and tolera-
bility of imatinib in SSc remain. In theory, the deﬁnite answers may
only be found in well-designed, randomized controlled trials. Several
obstacles, however, make large randomized-controlled trials in SSc a
great challenge: SSc is rare, which makes it difﬁcult to recruit large
study cohorts, and SSc can be life-threatening, which raises ethical is-
sues when treating patients with novel agents and placebos in partic-
ular over longer periods of time, keeping in mind that few classical
DMARDs might have at least marginal positive effects in a subset of
patients. Longer treatment periods are necessary, however, when
assessing the anti-ﬁbrotic efﬁcacy by the modiﬁed Rodnan skin score
or by changes in lung function, which are the standard primary out-
comes in clinical SSc trials.
Nevertheless, there may be another key to success: we believe
that proof-of-concept studies using speciﬁc and sensitive ﬁbrosis bio-
markers can bridge the gap between early clinical development and
large randomized-controlled trials in the future. Fibrosis biomarkers
may enable early clinical decision making and help to prevent late
clinical failure, in particular those that may respond rapidly to treat-
ment (e.g., changes in protein and mRNA levels of extracellular ma-
trix proteins, or marker genes for key-ﬁbrotic pathways) [107,108].
Nevertheless, these biomarkers still need careful characterization.
This approachmay also be useful for clinical trials in other ﬁbrotic dis-
eases that face similar hurdles as studies in SSc, including low patient
numbers and lack of sensitive and reliable outcome measures. We
hope that well-characterized ﬁbrosis biomarkers will help to triage
candidate anti-ﬁbrotic therapies and reduce the risk for late clinical
failures in the future.
When getting back to the imatinib story, three trials applied ﬁbrosis
biomarkers. Our colleagues and we found a reduction of col1a1 and ﬁ-
bronectin mRNA after 6 months of treatment and 6 months of follow-
up [3]. Pope et al. observed no change in a rather unselective panel of
25 ﬁbrotic and inﬂammatory biomarkers isolated from pulverized skin
biopsy tissue and plasma samples after 6 months of treatment [5]. Final-
ly, Spiera et al. found that skin thickness decreased during 12 months of
imatinib treatment, a marker that might be too insensitive for short-
term studies [6]. As preliminary experiences from a proof-of-concept
trial with 5HT2B-receptor antagonists suggest, treatment for as short
as 3 months (or even shorter)might be sufﬁcient to provide relevant in-
formation about the efﬁcacy of novel drugs that directly target ﬁbroblast
activation. Knowledge about molecular and pharmacological kinetics
suggests that changes on mRNA levels could even be expected withindays. To sumup the SSc imatinib trials, the study ﬁndings do not suggest
a strong anti-ﬁbrotic efﬁcacy of imatinib, butmodest anti-ﬁbrotic effects
cannot be excluded andmight be clinically relevant since effective anti-
ﬁbrotic therapies do not exist so far.3.2. Idiopathic pulmonary ﬁbrosis
In many aspects, the imatinib story in idiopathic pulmonary ﬁbro-
sis (IPF) resembles closely the one in SSc with many open questions
regarding its anti-ﬁbrotic efﬁcacy in patients. Promising results in ex-
perimental models of pulmonary ﬁbrosis prompted a double-blind
randomized, placebo-controlled trial in 119 patients with IPF. Pa-
tients received 600 mg imatinib daily or placebo for a period of up
to 96 weeks. The primary outcome was a combined measure of dis-
ease progression (deﬁned as >10% decline from baseline FVC) or
death, and secondary outcome measures included changes of DlCO,
resting paO2, 6-minute walk test and health assessment question-
naires among others [109].
Disappointingly, patients treated with imatinib did not show sig-
niﬁcant improvement in lung function and survival during the
follow-up period. Although the primary endpoints were not achieved,
imatinib-treated patients showed signiﬁcantly improved oxygenation
at 48 weeks compared with patients receiving placebo. In the last
value carried forward analysis, the positive effects on paO2 were
even sustained at 96 weeks. Imatinib was rather well-tolerated by pa-
tients with IPF as shown by similar adverse event rates between the
treatment and placebo study arms. This contrasts with the high
rates of peripheral edema in SSc, and indirectly supports the hypoth-
esis that imatinib might exacerbate vasculopathy in SSc patients and
that this may result in signiﬁcant adverse effects.
The study had several limitations, including a high percentage of
patients suffering from only mild or moderate disease, a poorly de-
ﬁned concomitant medication, and an insufﬁcient statistical power.
Thus, similar to the situation in SSc, this ﬁrst negative trial does not
preclude further consideration of imatinib and similar tyrosine kinase
inhibitors for clinical studies in IPF [110]. Imatinib might still have
mild to moderate anti-ﬁbrotic effects in IPF, which might be of clinical
relevance in a disease with limited established anti-ﬁbrotic treatment
options.
Apart from imatinib, the multi-tyrosine kinase inhibitor nintedanib
(BIBF 1120) has recently created a stir in the ﬁbrosis community. Al-
thoughRicheldi and colleagues formally failed tomeet the primary end-
point, too, the results of this large phase II clinical trial with 432 IPF
patients are considered promising due to a clear trend for the primary
outcome and signiﬁcant improvements for secondary outcome mea-
sures [111,112].
The anti-ﬁbrotic effects of nintedanib that blocks the tyrosine ki-
nases PDGFRα and β, VEGFR1, 2 and 3, as well as FGFR1, 2 and 3
were initially established in models of experimental pulmonary ﬁbro-
sis [113]. Based on these ﬁndings, Richeldi and colleagues studied
four different doses of nintedanib or placebo in patients diagnosed
with IPF according to published criteria over a treatment period of
12 months. Patients were not allowed to receive IPF-speciﬁc thera-
pies other than prednisone up to 15 mg per day on a stable dose.
Thus, concomitant treatment with azathioprine, N-acetyl-cysteine,
cyclophosphamide or experimental therapies was excluded [111].
In the group with the highest dose of nintedanib (150 mg twice
daily), Richeldi and colleagues found a non-signiﬁcant reduction
of 68% in annual decline in FVC compared to the placebo group
(p=0.06). The highest dose also resulted in signiﬁcantly fewer ex-
acerbations and a signiﬁcant increase in quality of life, both second-
ary endpoints in this study. The number of adverse events was
similar in all groups, but the proportion of serious adverse events
appeared to be lowest in the high-dose nintedanib-group. Although
generally well-tolerated, the highest dose of nintedanib was associated
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hepatotoxicity [111].
When compared to imatinib, the nintedanib data are more prom-
ising given the positive trend for the primary endpoint and signiﬁcant
ﬁndings for several secondary endpoints. These stimulating results
have already prompted further phase III studies in patients with IPF,
and trials in other ﬁbrotic diseases will likely follow soon. Interesting-
ly, Richeldi and coworkers followed another strategy with a different
trial design as we have suggested for future clinical studies in SSc and
other rare ﬁbrotic diseases, since the authors bypassed a proof-of-
concept trial with blood biomarkers. Lack of validated ﬁbrosis bio-
markers in the blood, lung function testing as an objective outcome
measure in IPF, and high conﬁdence in the efﬁcacy and tolerability
of study medication may have directed the decision for this strategy.
4. Dirty drug or selective inhibitor—what works best?
Fibrosis is an ultimate disease process instigated by different triggers
and propelled by various pro-ﬁbrotic pathways. Once initiated, the ﬁ-
brotic response may persist through several pro-ﬁbrotic pathways
that enhance and substitute for each other, even if a single pathway is
inhibited. Given the variety of pro-ﬁbrotic triggers and pathways, each
ﬁbrotic disease represents itself as a heterogeneous group of disorders.
Only few inherited ﬁbrotic diseases, such as the stiff skin syndrome,
may have a uniform disease pathogenesis with the activation of a single
or few pro-ﬁbrotic signaling cascades.
The results from the nitendanib and imatinib trials in pulmonary
ﬁbrosis and SSc suggest that less selective, ‘dirty’ small molecule in-
hibitors that target several signaling pathways can be effective in ﬁ-
brotic diseases, and that their use may not be limited by adverse
effects. This therapeutic approach may help to effectively treat a dis-
ease spectrum involving different pathologic key events and activa-
tion of various pro-ﬁbrotic pathways as found in ﬁbrotic diseases. It
may also prevent bypassing of the targeted pro-ﬁbrotic pathways by
alternative ones. Simultaneous blockade of several pathways theoret-
ically harbors a greater risk for potential side effects. This may be par-
ticularly true in SSc, in which many pathways may have opposing
roles in ﬁbrosis and vascular disease. In this context, targeted thera-
pies may have opposite outcomes on disease manifestations with im-
provement of ﬁbrosis but worsening of vasculopathy, as suspected for
the inhibition of PDGF signaling. Thus, simultaneous blockade of sev-
eral pro-ﬁbrotic pathways may not only show a higher efﬁcacy but
also necessitates more careful clinical evaluations in regard to poten-
tial side effects.
Classical pharmacology aims to target a molecular pathway in-
volved in the disease as speciﬁcally as possible to minimize undesir-
able side effects. By this selective approach, the risk of unexpected
side effects theoretically decreases. Given the clinical, pathological
and molecular heterogeneity of most ﬁbrotic diseases, potent anti-
ﬁbrotic effects in a broader spectrum of patients, however, may only
be achieved if the selected target acts as a core pro-ﬁbrotic pathway
or even as a common denominator of several pro-ﬁbrotic signaling
cascades.
In the long run, we believe that an increased speciﬁcity of anti-
ﬁbrotic therapies should be the ultimate goal of translational ﬁbrosis
research. To effectively apply these therapies and individualize anti-
ﬁbrotic treatment, however, patients with ﬁbrotic disease may need
more detailed molecular characterizations. Biomarkers that indicate
the activation of certain pro-ﬁbrotic (or inhibition of anti-ﬁbrotic)
pathways need to be developed to guide highly speciﬁc targeted ther-
apies. In some patients, combinations of several speciﬁc targeted thera-
pies may be necessary to achieve treatment goals, while in others,
applications of single agents might be sufﬁcient. As long as biomarker
techniques to individualize therapy are not well-elaborated, less selec-
tive therapies such as the multityrosine kinase inhibitors may be the
ﬁrst choice to effectively treat a spectrum of patients with ﬁbroticdisease. Prior to routine clinical use, however, these therapies need
careful preclinical and clinical evaluation to minimize the risks of clini-
cal failure because of a lack of either efﬁcacy or tolerability. In this
model, ﬁbrosis biomarkers that are sensitive and speciﬁc to detect
early changes of the anti-ﬁbrotic activity of candidate agents can help
to bridge the gap between preclinical investigations and clinical proof-
of-concept studies, both preceding large randomized-controlled clinical
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